Weekly ABIOMED, Inc. (NASDAQ:ABMD) Ratings

April 20, 2018 - By Julia Strobel

ABIOMED, Inc. (NASDAQ:ABMD) Corporate Logo
Big Money Sentiment decreased to 1.18 in Q4 2017. It has change of 0.12, from 2017Q3’s 1.3. The ratio turned negative due to ABIOMED, Inc. positioning: 19 sold and 110 reduced. 55 funds bought positions and 97 increased positions. Investors holded 38.51 million in 2017Q3 but now own 36.44 million shares or 5.39% less.
Palo Alto Ltd Liability Company owns 1.59 million shs. Thrivent Finance For Lutherans reported 69,935 shs stake. Redwood Invs Limited Liability Company, a Massachusetts-based fund reported 9,514 shs. Amer Century owns 963,517 shs. Signaturefd Ltd has invested 0.12% in ABIOMED, Inc. (NASDAQ:ABMD). Sei Invs accumulated 0.09% or 137,552 shs. 5,051 are held by Bank & Trust Of Montreal Can. Moreover, Tirschwell & Loewy Inc has 2.13% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 80,635 shs. Eagle Asset Mngmt has invested 0.27% in ABIOMED, Inc. (NASDAQ:ABMD). State Of Tennessee Treasury Department holds 40,000 shs or 0.03% of its capital. Advantus Management invested in 0.02% or 5,173 shs. Two Sigma Securities Llc has 1,720 shs. Citadel Lc reported 13,164 shs. Inv House Ltd Liability Corporation has invested 0.09% of its capital in ABIOMED, Inc. (NASDAQ:ABMD). Aperio Lc accumulated 17,706 shs.

ABIOMED, Inc. had 1 insider sale and 0 insider purchases since February 20, 2018. This’s net activity of $5.41 million.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

In total 8 analysts cover Abiomed (NASDAQ:ABMD). “Buy” rating has 7, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ABMD) has 88% bullish analysts. With $370.0 highest and $208.0 lowest [Target], Abiomed has $305.13 average [Target] or -0.43% below the current ($306.45) price. 12 are the (NASDAQ:ABMD)’s ratings reports on Apr 20, 2018 according to StockzIntelligence Inc. In Thursday, February 1 report Jefferies maintained it with “Buy” rating and $300.0 target. The company rating was maintained by Morgan Stanley on Friday, February 2. On Thursday, January 4 the firm has “Buy” rating given by Piper Jaffray. On Friday, February 2 the rating was maintained by Stephens with “Buy”. On Friday, February 16 the rating was maintained by SunTrust with “Buy”. On Thursday, November 2 the stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given by Jefferies. On Thursday, February 1 Piper Jaffray maintained the shares of ABMD in report with “Buy” rating. In Monday, April 9 report Stephens maintained it with “Buy” rating and $30000 target. On Thursday, December 21 the firm earned “Buy” rating by Jefferies. On Friday, February 2 the firm has “Buy” rating given by Guggenheim. Listed here are ABIOMED, Inc. (NASDAQ:ABMD) PTs and latest ratings.

09/04/2018 Broker: Stephens Rating: Buy New Target: $300.0000 Maintain
04/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $332 Initiates Coverage On
16/02/2018 Broker: SunTrust Rating: Buy New Target: $370.0 Maintain
02/02/2018 Broker: Stephens Rating: Buy New Target: $274.0 Maintain
02/02/2018 Broker: Leerink Swann Rating: Buy New Target: $300.0
02/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $204 New Target: $259 Maintain
02/02/2018 Broker: Guggenheim Rating: Buy New Target: $280.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $300.0 Maintain
01/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $300.0 Maintain
04/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $220.0 Maintain

The stock decreased 0.38% or $1.18 during the last trading session, hitting $306.45.Currently ABIOMED, Inc. is uptrending after 128.67% change in last April 20, 2017. ABMD has also 318,514 shares volume. ABMD outperformed by 117.12% the S&P 500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.The company has $13.57 billion market cap. It also provides continuum of care to heart failure patients.153.76 is the P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: